Ovarian Neoplasms: all 2,759 studies
Page 16 of 28. Open to participants first (736), then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 MonthsTerminatedNCT04826198Phase 1/2
- Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum CancerWithdrawnNCT04826029Not applicable
- Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex SequencingCompletedNCT04823871Not applicable
- 4FMFES-PET Imaging of Endometrial and Ovarian CancersCompletedNCT04823065Phase 1/2
- Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive SystemCompletedNCT04817501
- Spectroscopy in Ovarian CancerCompletedNCT04817449
- Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau TestStatus unknownNCT04812938
- Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerActive, not recruitingNCT04807166Phase 2
- Phase 1 Dose Escalation of ArtemiCoffeeCompletedNCT04805333Phase 1
- Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian CancersWithdrawnNCT04795596Phase 2/3
- Real-life Use of Niraparib in a Patient Access Program in NorwayCompletedNCT04785716
- Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to BevacizumabStatus unknownNCT04770376
- Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian CancerCompletedNCT04752865
- Olaparib, Durvalumab and UV1 in Relapsed Ovarian CancerActive, not recruitingNCT04742075Phase 2
- Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary TreatmentCompletedNCT04739527Phase 1
- Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorStatus unknownNCT04734665Phase 2
- Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian CancerTerminatedNCT04729608Phase 3
- Family History App in Personalized MedicineCompletedNCT04726319Not applicable
- Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian CancerCompletedNCT04724031
- Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04720807Phase 2
- A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian CancerCompletedNCT04718740Phase 1
- A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)TerminatedNCT04718675Phase 1/2
- A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian CancerTerminatedNCT04718376Phase 1
- Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian CancerCompletedNCT04716374
- Sentinel Lymph Node Assessment in Ovarian Cancer (TRSGO-SLN-OO5)Status unknownNCT04714931Not applicable
- OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OCActive, not recruitingNCT04713514Phase 2
- First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.SuspendedNCT04711161Phase 1
- A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsActive, not recruitingNCT04707248Phase 1
- Expanded Access Use of DKN-01 for the Treatment of Advanced Solid TumorsNo longer availableNCT04681248
- Infertility Survey Among Reproductive Age Women With Gynecological and Breast CancerActive, not recruitingNCT04678414
- Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP InhibitorsActive, not recruitingNCT04675320
- Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04673448Phase 1
- Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian CancerStatus unknownNCT04670978Phase 2
- EP0057 in Combination With Olaparib in Advanced Ovarian CancerCompletedNCT04669002Phase 2
- Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk DetectionTerminatedNCT04668521
- A Study of SGN-STNV in Advanced Solid TumorsTerminatedNCT04665921Phase 1
- Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.Status unknownNCT04661696Phase 2
- CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 1
- Cell-free DNA Methylation for Epithelial Ovarian CancerStatus unknownNCT04651946Phase 2
- A Training Set for the HRD Model in EOCStatus unknownNCT04651933
- A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian CancerCompletedNCT04651920
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
- Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With TumorsCompletedNCT04640480Phase 1
- A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS MutationActive, not recruitingNCT04625270Phase 2
- Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life StudyStatus unknownNCT04617470
- A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian CancerTerminatedNCT04614051Phase 1
- Risk Factors for Anatomic Leakage in Advanced Ovarian Cancer SurgeryCompletedNCT04604964
- Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian CancerCompletedNCT04593381Not applicable
- Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian CancerStatus unknownNCT04590625Phase 2
- A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South KoreaCompletedNCT04589039
- The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian CancerStatus unknownNCT04582552
- INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedNCT04580485Phase 1
- Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian CancerActive, not recruitingNCT04575961Phase 2
- Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.CompletedNCT04573933
- COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.CompletedNCT04570839Phase 1/2
- Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerStatus unknownNCT04566952Phase 2
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian CancerTerminatedNCT04562298Phase 1
- To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian CancerWithdrawnNCT04561817Phase 2
- Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesActive, not recruitingNCT04561362Phase 1/2
- Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese PatientsCompletedNCT04560452
- Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian CancerStatus unknownNCT04556539Phase 2
- Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian CancerStatus unknownNCT04556071Phase 2
- Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoidsStatus unknownNCT04555473
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)CompletedNCT04553926
- PF-07104091 as a Single Agent and in Combination TherapyActive, not recruitingNCT04553133Phase 2
- Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsActive, not recruitingNCT04550494Phase 2
- Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian CancerCompletedNCT04546373
- Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian CancerWithdrawnNCT04542603Phase 1
- Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer PatientsCompletedNCT04537702Not applicable
- Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized TrialCompletedNCT04534075Phase 3
- Living WELL: A Web-Based Program for Ovarian Cancer SurvivorsCompletedNCT04533763Not applicable
- Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UKCompletedNCT04532645
- Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1Status unknownNCT04523116
- A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer PatientsCompletedNCT04517357Phase 2
- Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational OncologyCompletedNCT04512209Not applicable
- Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary PeritonealActive, not recruitingNCT04511988Not applicable
- Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch SyndromeTerminatedNCT04508764Not applicable
- Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian CancerActive, not recruitingNCT04507841Phase 2
- 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological FindingsStatus unknownNCT04504110Phase 2
- A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ TumorsActive, not recruitingNCT04503278Phase 1
- Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerActive, not recruitingNCT04502602Phase 1
- Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported OutcomesCompletedNCT04501913
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1
- Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryActive, not recruitingNCT04498117Phase 3
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerActive, not recruitingNCT04491942Phase 1
- Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 MutationStatus unknownNCT04489706Not applicable
- TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
- A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR MutationStatus unknownNCT04473339Phase 3
- STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the NetherlandsActive, not recruitingNCT04470921
- Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnNCT04464967Phase 1/2
- Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2CompletedNCT04461457Early Phase 1
- Exemestane in Hormone Receptor Positive High Grade Ovarian CancerTerminatedNCT04460807Phase 3
- An INternational Frontline Ovarian Cancer Real World Management StudyCompletedNCT04460768
- Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian CancerCompletedNCT04457089Early Phase 1
- Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian CancerActive, not recruitingNCT04454450Not applicable
- Immunoassay and Regulation of Traditional Chinese Medicine on Cancer PatientsStatus unknownNCT04438564Not applicable
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibActive, not recruitingNCT04421963Phase 3
- Efficacy of Letrozole in Recurrent Ovarian CancerTerminatedNCT04421547Phase 3
- Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian CancerCompletedNCT04417192Phase 2
- Safety, Effectiveness and Operability of Using the New Tissue Containment System During Laparoscopic Ovarian CystectomyStatus unknownNCT04406597Not applicable